Catálogo de publicaciones - libros
Stem Cells and their Potential for Clinical Application
Nadja M. Bilko ; Boris Fehse ; Wolfram Ostertag ; Carol Stocking ; Axel R. Zander (eds.)
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
Hematology; Cancer Research; Molecular Medicine; Cell Biology; Immunology
Disponibilidad
| Institución detectada | Año de publicación | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | 2008 | SpringerLink |
Información
Tipo de recurso:
libros
ISBN impreso
978-1-4020-6467-8
ISBN electrónico
978-1-4020-6469-2
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
2008
Información sobre derechos de publicación
© Springer Netherlands 2008
Cobertura temática
Tabla de contenidos
Anti Thymocyte Globuline Allows for Successful Transplantation from HLA Mismatched Unrelated Donors
Axel R. Zander; Tatjana Zabelina; Francis Ayuk; Christine Wolschke; Olga Waschke; Gitta Amtsfeld; Thomas Eiermann; Hartmut Kabisch; Boris Fehse; Jürgen Berger; Rudolf Erttmann; Nicolaus M. Kröger
Allogeneic hemopoietic stem cell transplantation of matched unrelated donors carries an increased risk of graft versus host disease (GvHD) and transplant related mortality (TRM). We introduced ATG Fresenius at median dose of 90 mg/kg body weight as part of the conditioning regimen for prevention of serious GvHD. We compared 48 recipients of mismatched transplants with 170 recipients of an HLA-matched transplant. The mismatches involved one or two loci. The groups differed in age [HLA-matched: 33 years (0,9–61) HLA-mismatched: 21 years (0,9–51)] and graft source, bone marrow versus peripheral blood stem cell (matched 67% bone marrow, mismatched 83% bone marrow). They were comparable in diagnosis, stage of disease and conditioning. Key words: Mismatched unrelated donor, anti-thymocyte-globuline, stem cell transplantation
Palabras clave: Chronic Myelogenous Leukemia; Graft Versus Host Disease; Peripheral Blood Stem Cell; Unrelated Donor; Transplant Related Mortality.
V - Clinical Haematopoietic Stem Cell Transplantation | Pp. 263-274